Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Obeticholic Acid→

Obeticholic Acid PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
459789-99-2
Molecular formula
C26H44O4
Molecular weight
420.6 g/mol
Drug class
Farnesoid X receptor (FXR) agonistbile-acid analogue
Mechanism of action
Activates FXR in the liver and intestine, regulating bile-acid synthesis and transport and reducing hepatic bile-acid accumulation. It also modulates pathways involved in lipid and glucose metabolism.
Indications / reported uses
  • Historical US indication: treatment of primary biliary cholangitis in adults in combination with ursodeoxycholic acid when response to UDCA is inadequate, or as monotherapy when UDCA is not tolerated. US FDA accelerated approval was withdrawn in 2025; do not present as currently authorised in the US.

Sources: US FDA — Ocaliva approval withdrawal status · EMA — Ocaliva referral · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Farnesoid X receptor (FXR) agonist; bile-acid analogue

Mechanism of action

Activates FXR in the liver and intestine, regulating bile-acid synthesis and transport and reducing hepatic bile-acid accumulation. It also modulates pathways involved in lipid and glucose metabolism.

General use cases

  • Historical US indication: treatment of primary biliary cholangitis in adults in combination with ursodeoxycholic acid when response to UDCA is inadequate, or as monotherapy when UDCA is not tolerated. US FDA accelerated approval was withdrawn in 2025; do not present as currently authorised in the US.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Obeticholic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Obeticholic Acid Permitted Daily Exposure (PDE) report (the Obeticholic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Obeticholic Acid Occupational Exposure Limit (OEL) report (the Obeticholic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.